CRISPR-Based Diagnostics Market Report 2025

This CRISPR-Based Diagnostics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The CRISPR-based diagnostics market size has grown rapidly in recent years. It will grow from $4.35 billion in 2024 to $5.14 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth observed during the historic period can be attributed to factors such as an increase in healthcare expenditure, a rising demand for gene editing, a higher prevalence and incidence of chronic diseases, growing awareness of available treatments, and a rise in the prevalence of genetic disorders.

The CRISPR-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $9.92 billion in 2029 at a compound annual growth rate (CAGR) of 17.9%. The growth projected for the forecast period can be attributed to factors such as the increasing demand for rapid and accurate diagnostics, expanding applications in infectious disease detection, rising government and institutional funding, improved detection of antibiotic resistance, and growing awareness and acceptance of CRISPR technologies. Key trends anticipated during this period include point-of-care (POC) testing, the use of CRISPR-Cas12 and Cas13 systems, advancements in personalized medicine and genetic screening, integration with nanotechnology and biosensors, and the development of CRISPR-based early disease detection methods.

The growing incidence of infectious diseases is expected to drive the expansion of the CRISPR-based diagnostics market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread from person to person or through contaminated surfaces, food, water, or vectors such as insects. The rising frequency of these diseases is attributed to factors including globalization, antibiotic resistance, climate change, urbanization, population growth, habitat destruction, and limited access to healthcare. CRISPR-based diagnostics support the fight against infectious diseases by offering rapid and accurate pathogen detection, enabling early diagnosis, prompt intervention, and effective containment strategies. For example, in August 2024, data from the UK Health Security Agency (UKHSA), a UK-based executive agency, revealed that 368 measles cases were reported in England in 2023. This represented a nearly sevenfold increase from the 53 cases in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. As a result, the increasing incidence of infectious diseases is driving the growth of the CRISPR-based diagnostics market.

Major players in the CRISPR-based diagnostics market are increasingly forming strategic partnerships to improve access to rapid and accurate diagnostics through CRISPR-based point-of-care tests. A strategic partnership involves a long-term collaboration between organizations that combine their resources and expertise to achieve shared goals and strengthen their competitive edge. For example, in August 2023, CrisprBits Private Limited, a biotechnology company based in India, entered into a strategic collaboration with Molbio Diagnostics, an Indian molecular diagnostics company. This partnership focuses on developing CRISPR-based point-of-care tests (POCTs) that offer rapid, precise, and cost-effective diagnostic solutions for detecting pathogens and genetic markers. The goal is to enhance diagnostic accessibility in various environments, including resource-limited areas, while ensuring quick and accurate disease detection. By combining CrisprBits' CRISPR platform expertise with Molbio's manufacturing and distribution capabilities, the collaboration aims to introduce these tests to a global market.

In February 2024, Ginkgo Bioworks Holdings Inc., a biotechnology company based in the United States, acquired Proof Diagnostics Inc. for an undisclosed amount. The acquisition is intended to enhance Ginkgo's gene therapy services by incorporating Proof Diagnostics' OMEGA RNA-programmable nuclease technology, thereby improving its gene editing capabilities. This strategic move strengthens Ginkgo's ability to offer advanced solutions in therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based company that specializes in CRISPR-based molecular testing solutions for COVID-19.

Major players in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Beam Therapeutics, Intellia Therapeutics Inc., Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Verve Therapeutics, Editas Medicine, Epic Bio, Sherlock Biosciences, Addgene, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., and ToolGen Inc.

North America was the largest region in the CRISPR-based diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in CRISPR-based diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the CRISPR-based diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

CRISPR-based diagnostics refers to advanced molecular tools that utilize the CRISPR-Cas system to detect specific nucleic acid sequences with high precision and speed, enabling the identification of diseases or genetic markers. This technology offers groundbreaking capabilities in medical and genomic analysis. CRISPR-based diagnostics are used in applications such as detecting infectious diseases, identifying genetic disorders, and monitoring mutations in cancer research and treatment. It also holds significant potential in personalized medicine and point-of-care testing.

The primary products in CRISPR-based diagnostics include kits, buffer solutions, software, and other components. CRISPR diagnostic kits are ready-to-use tools designed for the rapid and accurate detection of specific genetic material, frequently applied in disease diagnosis and research. Techniques used in this process include recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and others. These diagnostics are used for both infectious and non-infectious diseases and are employed by hospitals, diagnostic centers, biotechnology companies, academic and research institutions, among others.

The CRISPR-based diagnostics market research report is one of a series of new reports that provides CRISPR-based diagnostics market statistics, including CRISPR-based diagnostics industry global market size, regional shares, competitors with CRISPR-based diagnostics market share, detailed CRISPR-based diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR-based diagnostics industry. This CRISPR-based diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.